Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.88
(
-0.77%
)
Bitcoin
74,404.50
(
0.62%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: acgood post# 86160

Wednesday, 11/11/2009 4:11:39 PM

Wednesday, November 11, 2009 4:11:39 PM

Post# of 257253
TEVA:

so this new [Copaxone] formulation would be the basis of an ANDA because of the differences between it and the original copaxone?

No, Teva will submit “low volume” Copaxone as a supplemental NDA. (As the owner of Copaxone, Teva would not ever be the applicant for a Copaxone ANDA.)


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now